Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.

Multiple myeloma — a malignancy of terminally differentiated plasma cells — is the second most common haematological malignancy. This Primer by Kumar et al. highlights the mechanisms and ...

Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood ...